Dublin, April 28, 2026 (GLOBE NEWSWIRE) — The “Medical Device Contract Development and Manufacturing Organization Market Size, Share & Trends Analysis Report by Product, Service, Class, Application, End Use, Region, and Segment Forecasts, 2026-2033” has been added to ResearchAndMarkets.com’s offering.
The global medical device contract development and manufacturing organization (CDMO) market is predicted to expand significantly, from USD 134.65 billion in 2025 to an estimated USD 354.60 billion by 2033. This growth, at a CAGR of 13.12% from 2026 to 2033, is propelled by emerging trends such as the growing inclination toward outsourcing, demand for advanced products, and the shift to home care and minimally invasive treatments.
The CDMO market’s expansion is primarily due to an uptick in OEMs seeking to outsource development and manufacturing. This approach helps OEMs manage regulatory complexities, minimize high capital expenditure, and access specialized engineering expertise. By partnering with CDMOs, OEMs are able to concentrate on R&D and commercialization, while benefiting from scalable production, process validation, and regulatory support.
The trend is pronounced in sectors like minimally invasive, implantable, and connected devices, where advanced manufacturing and compliance are critical. Outsourcing also hastens time-to-market through automation and smart quality systems, enhances cost efficiency, and mitigates risk by leveraging ISO-certified facilities. A notable development is Jabil’s partnership with TxSphere in January 2026, highlighting the reliance on CDMOs for complex drug-device products.
Further driving the market is the increased demand for cutting-edge medical devices, as OEMs delegate complex and technology-intensive manufacturing responsibilities. Factors like chronic disease prevalence, aging demographics, and the adoption of connected diagnostics and AI-enabled systems are pivotal in market acceleration. CDMOs are instrumental in precision manufacturing, electronics integration, and regulatory navigation, all bolstered by investments in advanced manufacturing technologies and automation. As digital health frameworks expand and regulatory processes streamline, the pace of commercialization quickens.
A key growth driver is the necessity for specialized expertise driven by rapid innovation and increased product complexity, which often outstrips the capabilities of many manufacturers. Present-day medical devices necessitate a fusion of advanced materials, embedded software, and stringent regulatory adherence, requiring a multidisciplinary approach. Many small and mid-sized OEMs lack the capability to design and scale such intricate products efficiently. Collaborating with CDMOs that offer design optimization, prototyping, advanced manufacturing, and compliance expertise allows companies to quicken market entry and curtail development risks.
The CDMO industry’s growth is also fueled by the shift toward home care solutions and minimally invasive treatments. Healthcare systems emphasize cost reduction, enhance patient comfort, and hasten recovery, thereby increasing the demand for wearable monitors and point-of-care diagnostics. These devices, needing advanced materials and precision engineering, are often manufactured by specialized CDMOs. In particular, home-use devices require meticulous testing and safety validation. Startups and small OEMs frequently depend on CDMOs for comprehensive support ranging from design and prototyping to manufacturing and regulatory guidance, underscoring CDMOs’ strategic significance.
Report Coverage
The report includes revenue forecasts, trend analysis from 2021 to 2033, segmented by product, service, class, application, end use, and region.
It covers:
- Product Outlook: Diagnostics, Therapeutics, Drug-Device Combinations
- Service Outlook: Contract Development, Manufacturing, Packaging, Regulatory Affairs, Others
- Class Outlook: Class I, II, III
- Application Outlook: Cardiovascular, Orthopedic, Ophthalmic, Diagnostic, Respiratory, Surgical Instruments, Dental, Others
- End Use Outlook: OEMs, Pharma & Biopharma Companies, Others
- Regional Outlook: North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Why You Should Buy This Report
- Comprehensive insights into market segments and regional dynamics.
- Understand the competitive landscape with profiles of key players.
- Identify emerging trends and critical market drivers.
- Receive actionable insights to explore new revenue streams and inform strategic decisions.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2025-2033 |
| Estimated Market Value (USD) in 2025 | $134.65 Billion |
| Forecasted Market Value (USD) by 2033 | $354.6 Billion |
| Compound Annual Growth Rate | 13.1% |
| Regions Covered | Global |
The leading players profiled in this Medical Device Contract Development and Manufacturing Organization market report include:
- Jabil Inc.
- Thermo Fisher Scientific Inc.
- Integer Holdings Corporation
- FLEX Ltd.
- Sanmina Corporation
- Celestica Inc.
- Phillips-Medisize
- Plexus Corp.
- Nipro Corporation
- Viant Technology LLC
- West Pharmaceutical Services, Inc.
- Mack Molding
- Cirtec Medical
- Cogmedix
- Synecco Ltd.
- TE Connectivity
- Keller Technology Corp.
- HDA Technology, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/52hn7h
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Medical Device Contract Development and Manufacturing Organization Market
